Germany: German Federal Patent Court releases new decision

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: German Federal Patent Court releases new decision

adobestock-62198618flag.jpg

In the present decision, the German Federal Patent Court dealt with the question of which point in time is decisive when considering advantages and technical effects of a claimed technical teaching. This question can be of importance both in the context of inventive step discussions in nullity cases and in the context of the technical-functional interpretation as applied by the infringement courts.

The German Federal Patent Court ruled that only the disclosure of the patent application would be decisive and that only those advantages and technical effects can be applied which the skilled person has been able to recognise at the filling date. According to the German Federal Patent Court, an objective enrichment of the prior art should only be considered as it is recognisable for a skilled person on the basis of the disclosure of the patent application or on the basis of his knowledge at the filling date. It is not sufficient that such an advantage or technical effect existed objectively unrecognised at the time of filing, but is only subsequently recognisable by the skilled person and made accessible as such.

In its first guideline, the German Federal Patent Court stated:

To the extent that the case-law and the literature refer to the granted patent with respect to a disclosure of advantages and effects, the relevant disclosure of the patent application must be taken into account instead – the granted patent does not represent an additional caesura for an admissible fall back on the original disclosure of the patent application within the limits of the exclusion of an extension of the scope of protection.

With its decision, the German Federal Patent Court has sparked a discussion on the relationship between the disclosure of a patent application and a disclosure of the later granted patent which may differ from the disclosure of the patent application. This discussion may also have an impact on the technical-functional interpretation as applied by the infringement courts, as they have so far mainly focused on the disclosure of the granted patent. Notably, in its decision Occlusion Device (BGHZ 189, 330 = GRUR 2011, 701 – Okklusionsvorrichtung), the German Federal Supreme Court stated that the interpretation of the claim features could possibly also be based on a difference between a published patent application and the later granted patent. It therefore remains to be seen how the infringement courts and the German Federal Supreme Court will position themselves in this regard.

Again, it must be noted that it is of crucial importance, when drafting patent applications, to sufficiently explain the advantages and technical effects to be achieved with the respective features in order to be able to argue accordingly in subsequent nullity proceedings or infringement proceedings.

stefan-bianchin-grau.jpg

Stefan Bianchin

Maiwald

Elisenhof, Elisenstraße 3

D-80335 München

Tel: +49 (0)89 747266-0

Fax: +49 (0)89 776424

more from across site and SHARED ros bottom lb

More from across our site

Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Aparna Watal, head of trademarks at Halfords IP, discusses why lawyers must take a stand when advising clients and how she balances work, motherhood and mentoring
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Gift this article